CRSP
HealthcareCRISPR Therapeutics AG
$55.15
+$1.38 (+2.57%)
Jan 5, 2026
Price History (1Y)
Analysis
CRISPR Therapeutics AG is a biotechnology company listed in the healthcare sector with a market capitalization of $5.26 billion. The company operates in the industry of biotechnology and employs 393 individuals. The financial health of CRISPR Therapeutics AG reveals significant losses, with net income totaling -$488,296,992 over the trailing twelve months. Margins are extremely low, with gross margin at 0.0% and operating margin at -14854.8%. The company's profitability is also indicated by a return on equity (ROE) of -25.3% and a return on assets (ROA) of -13.3%. The balance sheet shows $211.02 million in debt, but the company holds significant cash reserves totaling $1.92 billion. The valuation context for CRISPR Therapeutics AG is characterized by negative earnings, with an EBITDA loss of -$459,481,984 and a forward P/E ratio of -12.37. The price to book value is 2.70, while the price to sales ratio is 137.09. Revenue growth has been strong, with a year-over-year increase of 47.7%. However, dividend payments are not applicable, as the payout ratio is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Visit website →Key Statistics
- Market Cap
- $5.26B
- P/E Ratio
- N/A
- 52-Week High
- $78.48
- 52-Week Low
- $30.04
- Avg Volume
- 2.22M
- Beta
- 1.70
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Switzerland
- Employees
- 393